Johnson & Johnson Development Corporation
VC Fund
New Brunswick, United States
Johnson & Johnson Development Corporation is a VC fund in New Brunswick focused on Health Care and Biotechnology. Johnson & Johnson Development Corporation (JJDC) is the venture capital subsidiary of Johnson & Johnson. JJDC is comprised of experts and leaders in the health care and technology venture communities who identify early market indicators, health care trends, and strategic investment opportunities. Unlike traditional venture capital firms,JJDC determines the success of an investment’s performance not only in financial returns, but also in the viability of providing strategic growth options for Johnson & Johnson.JJDC plays an integral role in the identification of new business opportunities outside of Johnson & Johnson’s traditional portfolio and market presence. JJDC identifies new market opportunities and develops new businesses in emergent health care sectors while also creating support venture investments in alignment with the strategic objectives of Johnson & Johnson operating companies.
- Total investments:
- 130
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries Johnson & Johnson Development Corporation invests in
Stages Johnson & Johnson Development Corporation invests in
Countries Johnson & Johnson Development Corporation invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 10 contacts → | |||
Round size
- Series A
- $3M–$35M
- Series B
- $15M–$49M
- Series C
- $12M–$40M
Investment Focus
Industry
- Health Care 65 (50%)
- Biotechnology 60 (46%)
- Medical 39 (30%)
- Medical Device 30 (23%)
- Therapeutics 17 (13%)
Stage
- Series C 29 (22%)
- Series B 26 (20%)
- Series A 15 (12%)
- Funding Round 15 (12%)
- Series D 14 (11%)
Country
- United States 69 (53%)
- United Kingdom 3 (2%)
- Canada 2 (2%)
- Denmark 2 (2%)
- Switzerland 2 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Asish Xavier
Vice President, Venture Investments
|
Vice President, Venture Investments | Total investments: 14 | Find email | |
Kadir Kadhiresan
Vice President, Venture Investments
|
Vice President, Venture Investments | Total investments: 7 | Find email | |
James J. Bergin
Vice President Law
|
Vice President Law | Total investments: 0 | Find email | |
Jeanne Bolger
Vice President Venture Investing
|
Vice President Venture Investing | Total investments: 0 | Find email | |
Marian Nakada
Vice President, Venture Investments
|
Vice President, Venture Investments | Total investments: 1 | Find email | |
| See all 10 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Ronovo Surgical is an emerging medtech company focused on innovating minimally invasive (MIS) and digital surgery. | $67M / Series D / Sep 04, 2025 | ||
| Houston-based medical device startup Prana Thoracic, Inc. is dedicated to developing solutions for early intervention in lung cancer. We are an experienced team of surgeons, engineers and entrepreneurs on a mission to tackle lung cancer; the #1 cancer killer in the US.The paradigm of screening, detection, and early intervention that has beendeployed in other major cancers has so far eluded lung cancer. As a result, only 16% of lung cancers are found at an early stage and the current 5-year survival rate is < 20%. Recent changes to lung cancer screening guidelines have illuminated a path to improving outcomes in lung cancer. However, these advances rely on excising suspicious nodules and providing sufficient tissue for definitive diagnosis. We believe this is the missing piece of the puzzle, and physicians need a new generation of surgical oncology tools for lung cancer.Prana Thoracic plans to revolutionize the early diagnosis and treatment of lung cancer by making it easier and less invasive to deal with the rapidly growing number of early suspicious lung nodules; ensuring that we do not miss the window of opportunity to intervene early. | $3M / Series A / Jun 18, 2024 | ||
| Osteal Therapeutics is a clinical-stage specialty pharmaceutical company developing novel drug and device combination products for treating musculoskeletal infection. | $50M / Series D / Jun 05, 2024 | ||
| Osteal Therapeutics is a clinical-stage specialty pharmaceutical company developing novel drug and device combination products for treating musculoskeletal infection. | $23M / Series C / Sep 21, 2023 | ||
| Houston-based medical device startup Prana Thoracic, Inc. is dedicated to developing solutions for early intervention in lung cancer. We are an experienced team of surgeons, engineers and entrepreneurs on a mission to tackle lung cancer; the #1 cancer killer in the US.The paradigm of screening, detection, and early intervention that has beendeployed in other major cancers has so far eluded lung cancer. As a result, only 16% of lung cancers are found at an early stage and the current 5-year survival rate is < 20%. Recent changes to lung cancer screening guidelines have illuminated a path to improving outcomes in lung cancer. However, these advances rely on excising suspicious nodules and providing sufficient tissue for definitive diagnosis. We believe this is the missing piece of the puzzle, and physicians need a new generation of surgical oncology tools for lung cancer.Prana Thoracic plans to revolutionize the early diagnosis and treatment of lung cancer by making it easier and less invasive to deal with the rapidly growing number of early suspicious lung nodules; ensuring that we do not miss the window of opportunity to intervene early. | $3M / Series A / Oct 19, 2022 | ||
| Osteal Therapeutics is a clinical-stage specialty pharmaceutical company developing novel drug and device combination products for treating musculoskeletal infection. | $30M / Series B / Dec 29, 2021 | ||
| Binx Health is creating new categories of healthcare solutions that deliver on-demand testing to people where they need it most. With its proprietary, desktop, PCR-based point-of-care testing platforms and consumer mobile offerings, the company is redefining “convenient care” for the modern consumer | $104M / Series E / May 27, 2021 | ||
| XWPharma is a neuroscience biotech company that is researching new medicines for sleep, neuropsychiatric, and other neglected CNS illnesses. Bay Area, CA US. | $40M / Series C / Sep 17, 2020 | ||
| CVRx is a medical device company that develops implantable technology for the treatment of high blood pressure. Its products include Rheos implantable pulse generator that provides control and delivery of the activation energy; and Rheos carotid sinus leads, which conducts activation energy from the Rheos implantable pulse generator to the left andright carotid arteries. The company also offers a Rheos programmer system that communicates with the Rheos pulse generator. CVRx was founded in 2001 and is based in Minneapolis, Minnesota. | $50M / Private Equity / Jul 07, 2020 | ||
| CVRx is a medical device company that develops implantable technology for the treatment of high blood pressure. Its products include Rheos implantable pulse generator that provides control and delivery of the activation energy; and Rheos carotid sinus leads, which conducts activation energy from the Rheos implantable pulse generator to the left andright carotid arteries. The company also offers a Rheos programmer system that communicates with the Rheos pulse generator. CVRx was founded in 2001 and is based in Minneapolis, Minnesota. | $93M / Series G / Aug 09, 2019 | ||
| See all 130 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Johnson & Johnson Development Corporation invest in?
Johnson & Johnson Development Corporation invests primarily in Health Care, Biotechnology and Medical startups, most often at Series C and Series B stage. Most of the 130 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Johnson & Johnson Development Corporation's check size?
Johnson & Johnson Development Corporation typically joins rounds of $3M–$35M at Series A, $15M–$49M at Series B and $12M–$40M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Johnson & Johnson Development Corporation participates in.
How do I contact Johnson & Johnson Development Corporation?
Public channels for Johnson & Johnson Development Corporation include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Johnson & Johnson Development Corporation?
The team at Johnson & Johnson Development Corporation includes Asish Xavier (Vice President, Venture Investments), Kadir Kadhiresan (Vice President, Venture Investments) and James J. Bergin (Vice President Law), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
